Inhibitor Therapeutics, Inc. (INTI)

Market Cap	16.96M
Revenue (ttm)	n/a
Net Income (ttm)	-281,089
Shares Out	376.86M
EPS (ttm)	0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,643
Open	0.0450
Previous Close	0.0475
Day's Range	0.0450 - 0.0450
52-Week Range	0.0200 - 0.2000
Beta	-0.63
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About INTI

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed...

• Industry: Biotechnology
• Founded: 1992
• CEO: Nicholas Virca
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: INTI

Full Company Profile